The incidence of thyroid cancer (TC) has increased worldwide over the past four decades.
TC is divided into three main histological types: differentiated (papillary and follicular TC) …

Thyroid cancer is a common type of endocrine malignancy, and its incidence has been
steadily increasing in many regions of the world. Initiation and progression of thyroid cancer …

Inhibition of the BRAF (V600E) oncoprotein by the small-molecule drug PLX4032
(vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer …

Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising
incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with …

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon
which novel approaches to the management of thyroid cancer can be developed. A recent …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve
risk stratification of this cancer. Objective: The objective of the study was to investigate the …

Papillary thyroid cancer (PTC) is the most prevalent form of malignancy among all cancers of
the thyroid. It is also one of the few cancers with a rapidly increasing incidence. PTC is …

Purpose Based on the pivotal role of Ras-Raf-MAP-ERK signaling and vascular endothelial
growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II clinical trial …

The histopathologic diagnosis of follicular variant of papillary thyroid carcinoma (FVPCA)
can be difficult. Recent reports have suggested that this neoplasm may be frequently …